ClinicalTrials.gg
Not yet recruitingNCT07843953Updated Sep 28, 2026

Intraoperative Infusion of Dexmedetomidine Versus Lidocaine or Magnesium Sulphate for Enhanced Quality of Recovery After Spine Surgery Fixation

An interventional study of Group ( L): LICOCAINE and GROUP Dexmedetomidine in Opioid Free Anesthesia, Opioid Based Anesthesia and Spine Fixation Surgeries, sponsored by Zagazig University. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Zagazig University · Not applicable, Interventional, and Prevention

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Thoracolumbar fixation is a major spine surgery; it is performed to stabilize the spine after trauma, deformity or advanced degenerative disease. The primary surgical goals are to restore spinal alignment and achieve solid arthrodesis (fusion). From a surgical view, success is often measured by radiographic outcomes, hardware integrity and fusion rates. As anesthesiologists, we must recognize that technical success does not the same as optimal patient recovery.

This is why the concept of Quality of Recovery (QoR) becomes very important. QoR is a patient-centered outcome that covers more than the absence of surgical complications. It includes rapid return of physical function, pain control, psychological well-being, emotional stability and Patient satisfaction.

Therefore, our focus in the perioperative care shifts the focus from "did the surgery succeed?" to "how we can help the patient to recover physically, mentally, and functionally?" This approach is measured using patient-reported outcomes such as the QoR-15 or QoR-40 questionnaires.

Dexmedetomidine (Precedex) has become one of the most valuable medications in modern anesthesia, especially for surgeries associated with significant pain. As a highly selective α2-adrenergic agonist, dexmedetomidine provides a unique combination of analgesia, anxiolysis, and cooperative sedation without causing respiratory depression; it is helpful during painful procedures such as spine surgery.

When infused intraoperative; Precedex reduces central sensitization and diminishes the stress response to surgical stimuli, resulting in improved intraoperative hemodynamic stability, lower postoperative pain scores, reduced opioid requirements, and a smooth and calm recovery from anesthesia.

Intraoperative intravenous lidocaine infusion has become an important tool for improving postoperative pain control; especially in major surgeries. Although lidocaine is commonly known as a local anesthetic, when given systemically during surgery it works in several meaningful ways: it calms the central nervous system, reduces the body's inflammatory response to tissue trauma, and decreases pain sensitivity that often appears after anesthesia wears off.

Because of these combined effects, patients who receive IV lidocaine typically experience lower postoperative pain scores and need less opioid medications; therefore, avoid many opioid-related side effects such as nausea, sedation and constipation.

Lidocaine infusion not only reduces early postoperative pain but also help for faster recovery, earlier mobilization, and improved overall patient satisfaction.

Magnesium sulfate has become an increasingly valuable tool for anesthesiologists caring for patients undergoing long and painful surgical procedures. During major surgeries, the body's stress response can increase pain and make anesthetic management more challenging.

Magnesium works by blocking NMDA receptors, which are the key player in central sensitization and postoperative hyperalgesia. This means patients wake up with less pain, lower opioid requirements, and often more stable intraoperative vital signs. Many doctors preferred to use magnesium sulphate because it is inexpensive, widely available, and easy to administer as a slow infusion.

Read the detailed description

QoR -40 Questioner:

The QoR-40 contains 40 questions grouped into 5 dimensions:

1. Physical Comfort (12 items)

  1. Able to breathe easily
  2. Have had good sleep
  3. Have felt comfortable
  4. Have had a good appetite
  5. Able to enjoy food
  6. No nausea
  7. No vomiting
  8. Feeling rested
  9. Feeling warm and comfortable
  10. No shivering
  11. No sweating
  12. Have had good general comfort

2. Emotional State (9 items) 13. Been able to feel relaxed 14. Been in control 15. Been able to enjoy company of others. 16. Felt anxious 17. Felt angry or irritable 18. Felt depressed 19. Felt lonely 20. Felt confused 21. Felt frightened 3. Physical Independence (5 items) 22. Able to look after personal toilet and hygiene unaided 23. Able to write (or use your phone) 24. Able to speak normally 25. Able to wash yourself 26. Able to dress yourself 4. Psychological Support (7 items) 27. Able to communicate with family or friends 28. Able to communicate with hospital staff 29. Feeling supported by hospital staff 30. Feeling understood by others 31. Feeling supported by family or friends 32. Feeling able to share worries or concerns 33. Feeling encouraged by others 5. Pain (7 items) 34. Moderate pain 35. Severe pain 36. Headache 37. Muscle pains 38. Back pain 39. Sore throat 40. Pain affecting sleep

Scoring

Each item is scored on a 5-point Likert scale:

  1. = None of the time
  2. = Some of the time
  3. = Usually
  4. = Most of the time
  5. = All of the time Total score range: 40-200

    • 150-200 --- excellent recovery
    • 140-159 --- good recovery
    • Less than 140 --- moderate recovery
02

Conditions studied

  • Opioid Free Anesthesia
  • Opioid Based Anesthesia
  • Spine Fixation Surgeries
  • Opiod-Related Disorders

Keywords

  • Intraoperative Infusion of Dexmedetomidine versus Lidocaine or Magnesium Sulphate for Enhanced Quality of Recovery After, Spine Surgery Fixation
03

In context

Lead sponsor

Zagazig University is the lead sponsor of 462 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient acceptance.
  2. Patients age between 18-60 years old.

2- Both sexes. 3- Physical status from . 4- ≥ 18 kg/m2 \& ≤ 35 kg/m2. 5- Patient acceptance with written consent. 6- Elective lumbar fixation double level surgery

Exclusion criteria

Exclusion Criteria:

  1. Uncooperative patient.
  2. Allergy to study drugs.
  3. Patients on chronic alcohol, opioid, tranquilizer or sedative use.
  4. Pregnancy.
  5. Emergency surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
117 participants (estimated)

Study arms

  • Active comparator
    Group (L) LIDOCAINE

    the patient will receive lidocaine IV infusion, loading dose (1.5 mg) diluted in 10 cm 0.9% saline given bolus then (1.5-2 mg/kg/h) will start after induction of anesthesia until the end of surgery.

    Drug: Group ( L): LICOCAINE

  • Active comparator
    Group (D)

    the patient will receive Dexmedetomidine IV infusion, loading dose (0.5 -1 mcg/kg) diluted in 10 cm 0.9% saline given bolus then (0.2-0.7mcg/kg/h) will start after induction of anesthesia until the end of surgery.

    Drug: GROUP Dexmedetomidine

  • Active comparator
    Group (M)

    the patient will receive Magnesium sulphate IV infusion, loading dose (30 mg/kg diluted in 10 cm 0.9% saline over 10-30 min than 6-20 mg/kg/h) will start after induction of anesthesia until the end of surgery.

    Drug: Group M: Magnesium sulphate

Interventions

  • DrugGroup ( L): LICOCAINE

    the patient will receive lidocaine IV infusion, loading dose (1.5 mg) diluted in 10 cm 0.9% saline given bolus then (1.5-2 mg/kg/h) will start after induction of anesthesia until the end of surgery.

  • DrugGROUP Dexmedetomidine

    the patient will receive Dexmedetomidine IV infusion, loading dose (0.5 -1 mcg/kg) diluted in 10 cm 0.9% saline given bolus then (0.2-0.7mcg/kg/h) will start after induction of anesthesia until the end of surgery.

  • DrugMagnesium SulfateStudies of Magnesium SulfateMagnesium Sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    the patient will receive Magnesium sulphate IV infusion, loading dose (30 mg/kg diluted in 10 cm 0.9% saline over 10-30 min than 6-20 mg/kg/h) will start after induction of anesthesia until the end of surgery.

06

What researchers measure

Primary outcomes

  1. Quality of Recovery-40 score measured at 24 hours postoperatively

    Quality of Recovery-40 contains 40 questions grouped into 5 dimensions: 1. Physical Comfort (12 items) 2. Emotional State (9 items) 3. Physical Independence (5 items) 4. Psychological Support (7 items) Scoring Each item is scored on a 5-point Likert scale: 1. = None of the time 2. = Some of the time 3. = Usually 4. = Most of the time 5. = All of the time Total score range: 40-200 * 150-200 --- excellent recovery * 140-159 --- good recovery * Less than 140 --- moderate recovery

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. visual analogue scale

    pain intensity using visual analogue score after surgery by scale from 0 to 10 which 0 mean no pain and 10 mean maximium pain intensity

    Time frame: at 2,4,6,8,12,24,48 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974 Jun 22;2(5920):656-9. doi: 10.1136/bmj.2.5920.656. PubMed 4835444 ↗
  • Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5. doi: 10.1093/oxfordjournals.bja.a013366. PubMed 10740540 ↗
  • Almajed A, Aleissa S, Al Harbi A, AlQahtani BE, Alshehri A, Alhandi AA, Alhadlaq A, Abaalkhail M, Alhelal F. The Effects of Magnesium Sulfate on Postoperative Pain in Patients Undergoing Lumbar Spinal Surgery: A Systematic Review of Randomized Controlled Trials. Cureus. 2025 Jan 12;17(1):e77352. doi: 10.7759/cureus.77352. eCollection 2025 Jan. PubMed 39944433 ↗
  • Dahake JS, Verma N, Bawiskar D. Magnesium Sulfate and Its Versatility in Anesthesia: A Comprehensive Review. Cureus. 2024 Mar 17;16(3):e56348. doi: 10.7759/cureus.56348. eCollection 2024 Mar. PubMed 38633961 ↗
  • Foo I, Macfarlane AJR, Srivastava D, Bhaskar A, Barker H, Knaggs R, Eipe N, Smith AF. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. Anaesthesia. 2021 Feb;76(2):238-250. doi: 10.1111/anae.15270. Epub 2020 Nov 3. PubMed 33141959 ↗
  • Chu R, Umukoro N, Greer T, Roberts J, Adekoya P, Odonkor CA, Hagedorn JM, Olatoye D, Urits I, Orhurhu MS, Umukoro P, Viswanath O, Hasoon J, Kaye AD, Orhurhu V. Intravenous Lidocaine Infusion for the Management of Early Postoperative Pain: A Comprehensive Review of Controlled Trials. Psychopharmacol Bull. 2020 Oct 15;50(4 Suppl 1):216-259. doi: 10.64719/pb.4391. PubMed 33633427 ↗
  • Afrati SR, Lianou I, Kaspiris A, Marougklianis V, Kotanidou A, Pneumaticos SG. Analgesic and Neuroprotective Roles of Dexmedetomidine in Spine Surgery: A Systematic Review. Diseases. 2025 Jul 6;13(7):212. doi: 10.3390/diseases13070212. PubMed 40710002 ↗
  • 39491750

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — planned after the completion of the study publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: planned after the completion of the study publication

Access criteria: principal investigator

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Sep 28, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jan 1, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843953
Lead sponsor
Zagazig University
Responsible party
Asmaa Mohammed Galal El-Deen (Associative professor, Zagazig University) — Principal investigator
First posted
Sep 28, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Dec 15, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

asmaa mohammed galal el din, associative professor
Contact
asmaa.galal79@gmail.com
01271550089

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Magnesium Sulfate

Start the discussion